1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Moderna Pips Pfizer/BioNTech In Combo Jab Race

 
• By Elizabeth Cairns

The company reported a late-stage success with its COVID-19 and flu combo vaccine, and says it can hit the market next year.    

Moderna, Inc. has inched ahead of arch-rivals Pfizer Inc. and BioNTech SE in the race to get a combined COVID-19 and flu vaccine approved. Phase III data on mRNA-1083 suggests that the combo jab works better than marketed single-virus shots, and Moderna reckons it can get the product to market in time for next year’s flu season.

Key Takeaways
  • Moderna’s COVID-19 and flu vaccine mRNA-1083 has succeeded in a Phase III trial.
  • A similar shot from Pfizer and BioNTech could have Phase III data in the...

The trial assessed antibody responses in more than 8,000 adults aged 50 and over, splitting the cohort into two age groups. Among the older patients, Sanofi’s high-dose Fluzone was used...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

More from R&D

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.